Shire Development, LLC v. Watson Pharms., Inc.
Shire Development, LLC v. Watson Pharms., Inc., 2016-1785
In a suit alleging defendant’s infringement by filing an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration seeking to market a generic version of plaintiff’s mesalamine drug, LIALDA, the district court’s finding of infringement is reversed where defendant’s ANDA product does not satisfy the Markush group requirements in claim 1(b).
- Published 2017/02/10
- United States Federal Circuit